Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181.
M. Peeters
Consultant or Advisory Role - Amgen
Honoraria - Amgen
Research Funding - Amgen
T. J. Price
Consultant or Advisory Role - Amgen (U)
A. H. Strickland
Research Funding - Amgen
T. E. Ciuleanu
Honoraria - Amgen
W. Scheithauer
Consultant or Advisory Role - Amgen; Merck; Roche; Sandoz
Honoraria - Amgen; Bayer; Fresenius Biotech; Merck; Roche; Sandoz; Sanofi
S. O'Reilly
Research Funding - Amgen
M. M. Keane
No relevant relationships to disclose
D. R. Spigel
Consultant or Advisory Role - Amgen (U)
Y. Tian
Employment or Leadership Position - Amgen
Stock Ownership - Amgen
K. Krishnan
Employment or Leadership Position - Amgen
Stock Ownership - Amgen